Pliant Therapeutics Investor Relations Material
Latest events
Study Update
Pliant Therapeutics
Access the full event backlog
Slides, Transcripts, and Reports from 9,000+ public companies
Latest reports from Pliant Therapeutics Inc
Access all reports
Pliant Therapeutics, Inc. (PTI) is a clinical stage biopharmaceutical company developing DNA-based therapeutics that enable patients to reverse fibrosis and related diseases. The company's lead product candidate, PRTX-100, is a proprietary plasmid DNA therapeutic that has completed Phase 2 testing in nonalcoholic steatohepatitis (NASH). PTI owns the rights to exclusive plasmid-based therapies optimized for solid tumors including breast and pancreatic cancers. Pliant Therapeutics, Inc. was incorporated in 2015 and is based in South San Francisco, California.
Key slides for Pliant Therapeutics Inc
Oppenheimer 34th Annual Healthcare Life Sciences Conference (Virtual)
Pliant Therapeutics Inc
Oppenheimer 34th Annual Healthcare Life Sciences Conference (Virtual)
Pliant Therapeutics Inc
Latest articles
Sundar Pichai: CEO of Alphabet and Google
Explore Sundar Pichai's improbable journey from Chennai, India, to becoming one of the most powerful individuals on the planet.
19 Apr 2024
The Three Cornerstones of Serial Acquirer Success
Explore what is behind successful serial acquirers: efficient capital use, decentralization, and a strong focus on people.
19 Apr 2024
Companies That Had Their IPO in 2023: Cautious Optimism
The cautiously optimistic market in 2023 saw stocks rebounded upwards, and interest in IPOs picked up from the previous year.
15 Apr 2024
Ticker symbol
Country
🇺🇸 United States